CD183抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD183 mouse mAb against Hela (1) and L-02 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD183 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Ramos cells using CD183 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CD183 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using CD183 mouse mAb with DAB staining.    

  
  

CD183. also known as CXCR3. is a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family. It is primarily expressed on activated T cells, natural killer (NK) cells, and other immune cells, where it mediates chemotaxis in response to interferon (IFN)-inducible ligands such as CXCL9. CXCL10. and CXCL11. These ligands are often upregulated during inflammatory or immune responses, positioning CD183 as a key player in directing immune cell migration to sites of infection, autoimmune activity, or tumor microenvironments.

CD183 antibodies are critical tools for identifying and characterizing CXCR3-expressing cell populations, particularly Th1-polarized T cells, which are associated with type 1 immune responses. In research, these antibodies are widely used in flow cytometry, immunohistochemistry, and functional studies to investigate immune dysregulation in diseases like multiple sclerosis, rheumatoid arthritis, viral infections, and cancer. Clinically, CD183 has emerged as a potential therapeutic target, with antibodies or small-molecule inhibitors being explored to modulate immune cell trafficking in inflammatory disorders. However, its role in cancer remains complex, as CXCR3 signaling can either promote antitumor immunity or facilitate tumor progression depending on context. Monoclonal anti-CD183 antibodies (e.g., clones 1C6. G025H7) are commonly validated for specificity across human and murine models, aiding mechanistic studies of immune pathways. Ongoing research continues to unravel its dualistic functions, balancing pro-inflammatory and regulatory roles in disease pathogenesis.